Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein W1 and W3 are N and W2 and W4 are CR12, or W1 and W3 are CR12 and W2 and W4 are N. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPR119, such as diabetes and obesity.

Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPR119, such as diabetes and obesity.

Abstract: The present invention relates to compounds of the general formula I wherein X, Y, Z, A, Ar, R1, R2, R3, and R4 are as defined herein, which compounds are inhibitors of MNK2 and MNK1. The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds, and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of disorders related to undesired activity of MNK1 and/or MNK2 kinases.

Abstract: The present invention relates to novel compounds of formula (I): wherein m, n, R0, R1, R2, R3 and R4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Abstract: Method of linking an electronic information label (EIL) having a display, to an Item in an EIL system including the steps: registering an EIL ID for the EIL, registering an ITEM ID for the Item to be linked with the EIL, storing the registered EIL ID and the ITEM ID as link data in a link data register in the EIL system, optionally indicating the link status for the EIL via a system interface, sending link confirmation data from the EIL system to the EIL, indicating, in response to the confirmation data, the link status for the EIL by displaying a link status image on the EIL display, wherein the link status image is at least partly a predefined image stored in an EIL storing unit.

Abstract: A handheld device for personal use for communication with electronic labels (11) in an ESL system comprises, in addition to control means (55), memory means (61), transmission means (57) for transmitting a command to the electronic label, and one or more buttons (53, 53?) for user input, a receiver (63) for receiving informa-tion from a central unit (1) in the system. The information may comprise new com-mands, or an authorization code that may be included in commands sent to the labels for authorization of the handheld device.

Abstract: The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Abstract: An electronic label showing information about a product related to this electronic label on a display (9; 31), said electronic label being updated from a central control unit. According to the invention the electronic label comprises a replaceable front shell (5; 21) and a stationary communication part (3; 23) to which the front shell should be attached.

Abstract: An electronic label, which is wirelessly connected to a product information updating system, said label comprising at least one display adapted to display product information. The display has a transparent or semitransparent backside and is adapted to be lit up from behind by either an external light source, surrounding main lighting or a built-in light source.

Abstract: The present invention relates to compounds of formula (I): Formula (I) wherein U, P, W1, W2, W3, v, Y, Z, Rm, and Rm? are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Abstract: The invention relates to compounds of the general formula (I): wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are as

Abstract: An electronic pricing system, includes price label system server adapted to communicate with a price controlling application (PCA) server communicating price label information to price labels (PLs). The system is designed to generate control signals for updating price information related to at least two separate sales items that are both/all logically linked to an individual price label in the system, the price label being designed to receive the control signals and to display the price information for each item separately.

Abstract: The invention-provides 2, 3-, 4- or 5-substituted-N1-(arylsulfonyl)indole and (heteroaryl)indole compounds of the general formula (I): in which Ar, R2, R3, R4 and R5 are as defined in the specification. The compounds bind to the 5-HT6 receptor and are useful for the treatment and prophylaxis of disorders mediated by the 5-HT6 receptor, such as obesity and CNS disorders.

Abstract: An electronic label, which is wirelessly connected to a product information updating system, said label comprising at least one display (3; 11,13,15) adapted to display product information. According to the invention the display (3; 11,13,15) has a transparent or semitransparent backside and is adapted to be lit up from behind.

Abstract: The invention relates to compounds of the general formula (I): 1

Abstract: The invention relates to compounds of the general formula (I): wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ri

Abstract: The present invention relates to systems, devices and methods for communicating between a central control unit (16) and/or a hand-held communication device (17), and at least one electronic shelf label (1). The invention provides systems, devices and methods for detecting if authorised or unauthorised communication with said at least one electronic shelf label (1) has occurred. The invention also provides for space management compliance.

Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.

Abstract: A method of testing signal power margin in a wireless local area network (LAN). A peripheral unit is capable of responding to a message from said transceiver unit (TRX) by sending an acknowledgement signal (ACK) back to said transceiver unit (TRX). A situation in the network where the acknowledgement signal (ACK) power is reduced is simulated. Then, a message to said peripheral (ESL) is sent from said transceiver (TRX). It is registered whether or not an acknowledgement (ACK) from said peripheral (ESL) is received by the transceiver unit (TRX). A signal power margin test system for a local area network (LAN). A peripheral unit is capable of responding to a message from a transceiver unit (TRX) by sending an acknowledgement signal (ACK) back to said transceiver unit (TRX). The system comprises a control unit programmable to switch the relative signal power levels between a nominal power situation, and a simulated situation that corresponds to a system where the power margin is reduced.

Abstract: Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant Escherichia coli system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.